Aptar – revenue and profit growth does not mean better performance
Aptar (NYSE: ATR) creates dosing, dispensing and packaging products for the global beauty and phara sectors. Over the past 10 years, its revenue grew at revenue grew at 3.7% CAGR while PAT grew at 5.2% CAGR.
You would think that with top line and bottom line growth, this would be a good performance. However, it ROE its 2023 was about the same as that in 2012. This standstill return was because there was declining operating and capital efficiency.
As an investor, your focus is on profitability. The market is not going to re-rate the company is the growth is because it is using disproportionately more assets and capital to grow revenue and earnings.
Moral of the story? Do let companies distract you with the wrong metrics. Is Aptar then a terrible investment? Find out more on page 20 of INVEST https://notice.shareinvestor.com/email/newsletter/invest/pdf/Vol206-Invest-10May.pdf
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
